Terns Pharmaceuticals Inc... (TERN)
NASDAQ: TERN
· Real-Time Price · USD
8.45
0.19 (2.30%)
At close: Oct 09, 2025, 10:57 AM
2.30% (1D)
| Bid | 6.02 |
| Market Cap | 739.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -91.75M |
| EPS (ttm) | -1.03 |
| PE Ratio (ttm) | -8.2 |
| Forward PE | -6.34 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 10.73 |
| Volume | 146,991 |
| Avg. Volume (20D) | 1,096,656 |
| Open | 8.29 |
| Previous Close | 8.26 |
| Day's Range | 8.29 - 8.50 |
| 52-Week Range | 1.86 - 8.78 |
| Beta | -0.04 |
| Ex-Dividend Date | n/a |
About TERN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TERN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TERN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-5.64%
TERN stock has given up its prior gain. Terns Phar...
Unlock content with
Pro Subscription
3 months ago
-5.64%
Terns Pharmaceuticals shares are trading higher after the company announced it will highlight data from the completed Phase 1 study of TERN-601 at the American Diabetes Association 85th Scientific Sessions. Also, the company completed enrollment for the Phase 2 FALCON trial.
1 month ago · https://thefly.com
Terns Pharmaceuticals assumed with a Neutral at H.C. WainwrightH.C. Wainwright assumed coverage of Terns Pharmaceuticals with a Neutral rating and $7.44 price target. The firm is cautiously optimistic on TERN-701 and TERN-601 as it awaits "differentiation data." ...
2 months ago · fool.com
Terns (TERN) Q2 Net Loss Narrows 16%Terns (TERN) Q2 Net Loss Narrows 16%
2 months ago · seekingalpha.com
Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology CatalystsTerns Pharmaceuticals, Inc. offers two differentiated late-stage assets—TERN-701 for CML and TERN-601 for obesity—with major data catalysts expected in Q4 2025. TERN-701 shows early signs of best-in-c...